October 3, 2022
Via: PharmaphorumAmylyx Pharmaceuticals’ Relyvrio – a new treatment for amyotrophic lateral sclerosis (ALS) approved by the FDA on Thursday, after review of the data from its phase 2 trial – was the next day set at a list price of $158,000 […]
September 26, 2023
September 21, 2023
September 19, 2023
September 14, 2023
September 7, 2023
September 1, 2023
September 19, 2023
September 5, 2023